Setareh Shamsili

Dr. Setareh Shamsili has taken the helm of Coretag at the combined role of CEO and CMO, since April 2024. A seasoned oncology drug development veteran, Setareh brings more than 28 years of clinical oncology and drug development expertise, at key and executive/C-suite levels, to Coretag. Dr. Shamsili has been instrumental both strategically and operationally, in successful fundraising activities, entering Nasdaq IPOs, and establishing strategic alliances, as well as moving forward the assets of respective companies from early translational stage towards clinical success. Setareh is an MD, board certified in internal medicine with focus on oncology, with a latest degree of Ph.D. in Oncology from the international Erasmus Medical University in Rotterdam, Netherlands and a Global Strategic Leadership from University of Pennsylvania Wharton Business School, USA. Dr. Shamsili has served at the likes of Astellas, Merus, Selvita/ Ryvu, Boehringer Ingelheim and more!